|
|
The natural course of bacillus Calmette-Guérin induced bladder lesions: A long-term follow-up study and systematic review |
Chong Maa,Shuxiong Zengb,Lihe Daic,Huan Hand,Ruixiang Songb,Jinshan Xub,Xing Aia,*( ),Chuanliang Xub,*( )
|
a Department of Urology, The Third Medical Center of PLA General Hospital, Beijing, China b Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China c Department of Urology, The 943 Hospital of Joint Logistics Support Force of Chinese PLA, Gansu, China d Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China |
|
|
Abstract Objective Bacillus Calmette-Guérin (BCG) instillation is the standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. Nevertheless, its toxicity often causes bladder complications. On follow-up cystoscopy, post-BCG bladder lesions can be pathologically benign, urothelial carcinoma recurrence, or other types of bladder malignancy. Only a small number of case reports have been published on post-BCG bladder lesions. Their clinical features, natural course, and management remain unknown. Methods We retrospectively studied cystoscopic videos and medical records of BCG-treated bladder cancer patients at our center. During a long-term follow-up, we took biopsies on tumor-like lesions and described their changes. In addition, we summarized previous studies on post-BCG bladder lesions by systematic literature searching and review. Results We described a series of three cases with post-BCG bladder lesions mimicking tumor recurrence from a total of 38 cases with follow-up data for more than 5 years. Those lesions could last, grow, or disappear spontaneously, and remain pathological benign for years. In systematic review, we identified and analyzed a total of 15 cases with post-BCG bladder lesions with detailed clinical information. Eleven of the 15 were benign and have a good prognosis with nephrogenic adenoma being the most common pathological type. Conclusion Based on previous studies and our experience, benign lesions after BCG instillation cannot distinguish with cancer recurrence by cystoscopy alone, even under narrow band imaging mode. Nonetheless, given most of them have a good prognosis, random biopsy or transurethral resection might be spared in the patients with long-term negative biopsy and urine cytology.
|
Received: 15 October 2022
Available online:
|
Corresponding Authors:
Xing Ai,Chuanliang Xu
E-mail: aixing0007@163.com;chuanliang_xu@126.com
|
|
|
Case | Age,year | Sex | BCa before BCG | BCG | Time fromBCG tolesion,month | Cystoscopy | Treatment | Follow-uptime, year | Outcome | Recurrence, n | Pathology | Strain | Dosage,mg | Schedule | Symptom | 1 | 53 | Male | 3 | Ta HG | Danish | 80 | 6 weekly maintenance 3 years | Frequencydysuria | 14 | Papillaryneoplasms | Follow-up and biopsy | 10 | No UC recurrence | 2 | 47 | Male | 0 | Ta HG | Danish | 80 | 6 weekly maintenance 1 year | Frequencyurgency | 4 | Papillaryneoplasmsarising from velvet-likemucosalerythema | Follow-up and biopsy | 7 | No UC recurrence | 3 | 67 | Male | 1 | Ta HG | Danish | 80 | 6 weekly maintenance 1 year | Frequencyurgencypain fever | 12 | Velvet-likeneoplasms | Follow-up and biopsy | 6 | No UC recurrence |
|
Clinical information of three cases with post-BCG tumor-like lesions.
|
|
The post-BCG tumor-like lesion changes on cystoscope and microscope of Case 1. (A) The tumor-like inflammatory lesion; (B) Hematoxylin-eosin staining image of chronic inflammation; (C) The tumor-like nephrogenic adenoma; (D) Hematoxylin-eosin staining image of nephrogenic adenoma. The red circle highlights the post-BCG lesion. BCG, bacillus Calmette-Guérin.
|
|
Flow diagram of study reviewing and selection. BCG, bacillus Calmette-Guérin.
|
[1] |
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA 2020; 324:1980-91.
|
[2] |
Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022; 81:75-94.
|
[3] |
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:244-58.
doi: 10.1016/j.annonc.2021.11.012
|
[4] |
Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS 2020; 128:92-103.
doi: 10.1111/apm.13011
pmid: 31755155
|
[5] |
Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007; 61: 299-305.
doi: 10.1016/j.biopha.2007.05.004
pmid: 17604943
|
[6] |
Swietek N, Waldert M, Rom M, Schatzl G, Wiener HG, Susani M, et al. The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature. J Urol 2012; 188:748-53.
doi: 10.1016/j.juro.2012.05.015
pmid: 22819422
|
[7] |
Brausi M, Oddens J, Sylvester R, Bono A, Van De Beek C, Van Andel G, et al. Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genitourinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69-76.
|
[8] |
Stilmant MM, Siroky MB. Nephrogenic adenoma associated with intravesical bacillus Calmette-Guerin treatment:a report of 2 cases. J Urol 1986; 135:359-61.
|
[9] |
Hidoussi A, Slama A, Jaidane M, Zakhama W, Youssef A, Sorba NB, et al. Eosinophilic cystitis induced by bacillus Calmette-Guerin (BCG) intravesical instillation. Urology 2007; 70:e9-10. https://doi.org/10.1016/j.urology.2007.07.032.
|
[10] |
Mehanni S, Joseph K, Casanas B, Greene J. Mycobacterium abscessus granulomatous cystitis in a patient with superficial bladder cancer. Infect Dis Clin Pract 2014; 22:116-7.
doi: 10.1097/IPC.0b013e31828875e6
|
[11] |
Smith PJ, Lotan Y, Raj GV, Sagalowsky AI, Margulis V. Assessing treatment response after induction bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can postinduction random bladder biopsies be avoided? Cytopathology 2014; 25:108-11.
doi: 10.1111/cyt.12064
pmid: 23551700
|
[12] |
Takamatsu K, Matsumoto K, Kikuchi E, Ogihara K, Hayakawa N, Tanaka N, et al. Can random bladder biopsies be eliminated after bacillus Calmette-Guerin therapy against carcinoma in situ? Int Urol Nephrol 2021; 53:465-9.
|
[13] |
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163:1124-9.
pmid: 10737480
|
[14] |
Partin A, Dmochowski R, Kavoussi L, Peters C. and CIS.Management strategies for non-muscle-invasive bladder cancer (Ta, T1, In: Campbell-Walsh-WeinUrology. 12th ed. Canada: Elsevier; 2021. p. 14193-305.
|
[15] |
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4:1. https://doi.org/10.1186/2046-4053-4-1.
|
[16] |
Str?ck V, Dotevall L, Sandberg T, Gustafsson CK, Holm?ng S. Late bacille Calmette-Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment. BJU Int 2011;107:1592-7.
|
[17] |
Garcia C, Jina H, Bergersen P, Chalasani V. Bladder contractureda rare and serious side effect of intravesical bacillus Calmette-Guérin therapy. Urol Case Rep 2016; 4:22-4.
doi: 10.1016/j.eucr.2015.10.003
pmid: 26793570
|
[18] |
Oyama N, Tanase K, Akino H, Mori H, Kanamaru H, Okada K. Nephrogenic adenoma in a patient with transitional cell carcinoma of the bladder receiving intravesical bacillus Calmette-Guerin. Int J Urol 1998; 5:185-7.
pmid: 9559850
|
[19] |
Kilciler M, Tan O, Ozgok Y, Tahmaz L, Deveci S, Erduran D. Nephrogenic adenoma of the bladder after intravesical bacillus Calmette-Guerin treatment. Urol Int 2000; 64:229-32.
pmid: 10895092
|
[20] |
Nakatani T, Kuratsukuri K, Uchida J, Sugimura K, Kuroki Y, Morikawa Y. Nephrogenic adenoma of the bladder: two case reports and literature review. Hinyokika Kiyo 2002; 48:463-6.
pmid: 12229190
|
[21] |
Numakura S, Morikawa T, Ushiku T, Toyoshima T, Fukayama M. Langerhans cell histiocytosis of the urinary bladder in a patient with bladder cancer previously treated with intravesical bacillus Calmette-Guerin therapy. Pathol Res Pract 2014; 210: 123-6.
doi: 10.1016/j.prp.2013.11.005
pmid: 24332601
|
[22] |
Kr?nig M, Jilg C, Burger D, Langer M, Timme-Bronsert S, Werner M, et al. BCG induced necrosis of the entire bladder urothelium. Urol Case Rep 2015; 3:161-3.
doi: 10.1016/j.eucr.2015.06.002
pmid: 26793538
|
[23] |
Sakatani T, Adachi Y, Sakaida N, Atsuta T, Magaribuchi T, Taki Y, et al. Nephrogenic adenoma in elderly patients: three case reports. Mol Clin Oncol 2016; 5:253-6.
pmid: 27446559
|
[24] |
Brenner DW, Yore LM, Schellhammer PF. Squamous cell carcinoma of bladder after successful intravesical therapy with bacillus Calmette-Guerin. Urology 1989; 34:93-5.
pmid: 2763404
|
[25] |
Yurdakul T, Avunduk MC, Piskin MM. Pure squamous cell carcinoma after intravesical BCG treatment: a case report. Urol Int 2005; 74:283-5.
|
[26] |
Arenas LF, Fontes DA, Pereira EM, Hering FL. Sarcomatoid carcinoma with osseous differentiation in the bladder. Int Braz J Urol 2006; 32:563-5.
pmid: 17081326
|
[27] |
Morozumi K, Namiki S, Kudo T, Aizawa M, Ioritani N, Sakamoto K, et al. Transdifferentiation of small cell carcinoma of the urinary bladder from urothelial carcinoma after transurethral resection of a bladder tumor, intravesical bacillus Calmette-Guerin instillation, and chemotherapy: a case report. Case Rep Oncol 2016; 9:786-91.
|
[28] |
Porcaro AB, D'Amico A, Ficarra V, Balzarro M, Righetti R, Martignoni G, et al. Nephrogenic adenoma of the urinary bladder: our experience and review of the literature. Urol Int 2001; 66:152-5.
pmid: 11316978
|
[29] |
Bassi P, Milani C, Meneghini A, Garbeglio A, Aragona F, Zattoni F, et al. Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer. Urology 1992; 40:175-9.
pmid: 1502759
|
[30] |
Bilen CY, ? zen H, Aki FT, Aygün C, Ekici S, Kendi S. Clinical experience with BCG alone versus BCG plus epirubicin. Int J Urol 2000;7:206-9.
|
[31] |
Kunju LP. Nephrogenic adenoma: report of a case and review of morphologic mimics. Arch Pathol Lab Med 2010; 134: 1455-9.
|
[32] |
Orihuela E, Herr HW, Pinsky CM, Whitmore Jr WF. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987; 60:326-33.
doi: 10.1002/1097-0142(19870801)60:3<326::aid-cncr2820600309>3.0.co;2-5
pmid: 3594369
|
[33] |
Zeng S, Yu X, Ma C, Zhang Z, Song R, Chen X, et al. Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Medicine (Baltim) 2015; 94:e2176. https://doi.org/10.1097/MD.0000000000002176.
|
[34] |
Hurle R, Lazzeri M, Vanni E, Lughezzani G, Buffi N, Casale P, et al. Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project. J Urol 2018; 199:401-6.
doi: S0022-5347(17)77391-0
pmid: 28847481
|
[35] |
Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, et al. Reported use of intravesical therapy for non-muscleinvasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int 2012; 110:967-72.
doi: 10.1111/bju.2012.110.issue-7
|
[36] |
Kresowik TP, Griffith TS. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009; 1:281-8.
doi: 10.2217/1750743X.1.2.281
pmid: 20046960
|
[37] |
Nesi G, Nobili S, Cai T, Caini S, Santi R. Chronic inflammation in urothelial bladder cancer. Virchows Arch 2015; 467:623-33.
doi: 10.1007/s00428-015-1820-x
|
[38] |
Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. J Pathol 2019; 249: 151-65.
doi: 10.1002/path.v249.2
|
[1] |
Zahid Lepara,Jasmin Alić,Orhan Lepara,Hajrudin Spahović,Almir Fajkić. Antioxidant status in patients with bladder cancer regarding cancer stage and grade[J]. Asian Journal of Urology, 2023, 10(2): 182-188. |
[2] |
Victor Chalfant,Michael L. BluteJr.,Peter Silberstein. Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013[J]. Asian Journal of Urology, 2023, 10(1): 9-18. |
[3] |
Junjie Fan,Hua Liang,Jinhai Fan,Lei Li,Guanjun Zhang,Xinqi Pei,Tao Yang,Dalin He,Kaijie Wu. Diagnostic accuracy of cystoscopic biopsy for tumour grade in outpatients with urothelial carcinoma of the bladder and the risk factors of upgrading[J]. Asian Journal of Urology, 2023, 10(1): 19-26. |
[4] |
Chinna Babu Dracham,Narendra Kumar,Santosh Kumar,Arun Elangovan,Budhi Singh Yadav,Ravimohan S. Mavuduru,Anupam Lal,Pramod K. Gupta,Rakesh Kapoor. A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer[J]. Asian Journal of Urology, 2022, 9(3): 318-328. |
[5] |
Yuvaraja B. Thyavihally,Preetham Dev,Santosh Waigankar,Abhinav Pednekar,Nevitha Athikari,Abhijit Raut,Archan Khandekar,Naresh Badlani,Ashishkumar Asari. Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)[J]. Asian Journal of Urology, 2022, 9(2): 157-164. |
[6] |
Lexiaochuan Wen,Cameron J. Britton,Rohan Garje,Benjamin W. Darbro,Vignesh T. Packiam. The emerging role of somatic tumor sequencing in the treatment of urothelial cancer[J]. Asian Journal of Urology, 2021, 8(4): 391-399. |
[7] |
Marcio Covas Moschovas,Kulthe Ramesh Seetharam Bhat,Cathy Jenson,Vipul R. Patel,Gabriel Ogaya-Pinies. Robtic-assisted radical cystectomy: Literature review[J]. Asian Journal of Urology, 2021, 8(1): 14-19. |
[8] |
Hugo Otaola-Arca,Rafael Coelho,Vipul R. Patel,Marcelo Orvieto. Totally intracorporeal robot-assisted urinary diversion for bladder cancer (Part 1). Review and detailed characterization of ileal conduit and modified Indiana pouch[J]. Asian Journal of Urology, 2021, 8(1): 50-62. |
[9] |
Hugo Otaola-Arca,Kulthe Ramesh Seetharam Bhat,Vipul R. Patel,Marcio Covas Moschovas,Marcelo Orvieto. Totally intracorporeal robot-assisted urinary diversion for bladder cancer (part 2). Review and detailed characterization of the existing intracorporeal orthotopic ileal neobladder[J]. Asian Journal of Urology, 2021, 8(1): 63-80. |
[10] |
Abhishek Tripathi,Shilpa Gupta. Androgen receptor in bladder cancer: A promising therapeutic target[J]. Asian Journal of Urology, 2020, 7(3): 284-290. |
[11] |
Weibin Xie,Junming Bi,Qiang Wei,Ping Han,Dongkui Song,Lei Shi,Dingwei Ye,Yijun Shen,Xin Gou,Weiyang He,Shaogang Wang,Zheng Liu,Jinhai Fan,Kaijie Wu,Zhiwen Chen,Xiaozhou Zhou,Chuize Kong,Yang Liu,Chunxiao Liu,Abai Xu,Baiye Jin,Guanghou Fu,Wei Xue,Haige Chen,Tiejun Pan,Zhong Tu,Tianxin Lin,Jian Huang. Survival after radical cystectomy for bladder cancer: Multicenter comparison between minimally invasive and open approaches[J]. Asian Journal of Urology, 2020, 7(3): 291-300. |
[12] |
Sunny Goel,Rahul J. Sinha,Ved Bhaskar,Ruchir Aeron,Ashish Sharma,Vishwajeet Singh. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade[J]. Asian Journal of Urology, 2019, 6(3): 222-229. |
[13] |
Brian T. Hanyok,Mary M. Everist,Lauren E. Howard,Amanda M. De Hoedt,William J. Aronson,Matthew R. Cooperberg,Christopher J. Kane,Christopher L. Amling,Martha K. Terris,Stephen J. Freedland. Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH[J]. Asian Journal of Urology, 2019, 6(3): 242-248. |
[14] |
Dominique Thomas,Kevin C. Zorn,Nadir Zaidi,Stephanie Ashley Chen,Yiye Zhang,Alexis Te,Bilal Chughtai. Does urodynamics predict voiding after benign prostatic hyperplasia surgery in patients with detrusor underactivity?[J]. Asian Journal of Urology, 2019, 6(3): 264-269. |
[15] |
Daniel A. Wollin,Adam G. Kaplan,Glenn M. Preminger,Pietro Manuel Ferraro,Antonio Nouvenne,Andrea Tasca,Emanuele Croppi,Giovanni Gambaro,Ita P. Heilberg. Defining metabolic activity of nephrolithiasis - Appropriate evaluation and follow-up of stone formers[J]. Asian Journal of Urology, 2018, 5(4): 235-242. |
|
|
|
|